Two wet spots stained a pink sheet, and a pair of pillows had been cast aside.

NEWYORKER: The House Behind a Weeping Cherry

While these are illiquid pink sheet shares, Raff is optimistic.

FORBES: New Nano Protection Against HIV And Herpes

On Dec. 17, 2001, The Pink Sheet, a medical newsletter, reported that multiyear studies on Vioxx would begin in 2002, and that Merck was expecting a 12-month patient follow-up.

FORBES: The Vioxx Safety Study Merck Didn't Do

On Sept. 22, The Pink Sheet, a medical trade publication, reported the FDA had said that Pfizer received an "approvable letter" from the FDA. Such letters are not approvals but instead a kind of delay, saying that most of the data needed for approval are in but that additional steps need to be taken if the drug is to reach the market.

FORBES: Pfizer Plays A Guessing Game

The FBI and the U.S. Attorney for the Central District of California have been investigating him since 2003 for fraud in another pink-sheet-listed company, NuWay Medical.

FORBES: Magazine Article